SOX5 Antibody

What is SOX5 and what is its biological significance?

SOX5 (Sex determining region Y-box protein 5) is a member of the SOX family of transcription factors identified by the conserved homology of the high-mobility group DNA-binding motif. This protein plays a critical role in the regulation of embryonic development and has been implicated in various pathological processes. SOX5 functions primarily as a transcriptional regulator involved in cell fate determination and differentiation across multiple tissue types. The biological significance of SOX5 extends to both developmental processes and disease states, with particular relevance to chondrogenesis, neurogenesis, and various cancers including prostate cancer, glioblastoma, hepatocellular carcinoma, osteosarcoma, and nasopharyngeal carcinoma .

What are the known isoforms of SOX5 and how do they differ functionally?

SOX5 exists in five distinct isoforms with molecular masses of 42, 71, and 82-84 kDa. These isoforms arise from alternative splicing and exhibit tissue-specific expression patterns. The longer isoforms (L-SOX5) contain additional coiled-coil domains that facilitate protein-protein interactions and oligomerization, which are absent in the shorter isoform (S-SOX5). This structural difference significantly impacts their functional capabilities, with L-SOX5 demonstrating enhanced DNA-binding efficiency and more potent transcriptional regulation. The 42 kDa isoform is predominantly expressed in testis, while the larger isoforms (71-84 kDa) are more broadly expressed across multiple tissues. Researchers should be aware of these isoform differences when designing experiments to study SOX5 function, as antibody reactivity and experimental outcomes may vary depending on which isoforms are present in their experimental system .

What applications are SOX5 antibodies typically used for in research settings?

SOX5 antibodies are employed across multiple experimental applications in research settings. Based on published literature, the primary applications include Western Blotting (WB) with recommended dilutions ranging from 1:2000 to 1:10000, Immunohistochemistry (IHC), Immunofluorescence (IF), and Enzyme-Linked Immunosorbent Assay (ELISA). These antibodies have demonstrated reactivity with human and mouse samples, with cited reactivity extending to rat samples as well. For optimal results in each application, researchers should conduct preliminary titration experiments to determine the ideal antibody concentration for their specific experimental system. The versatility of SOX5 antibodies makes them valuable tools for investigating SOX5 expression, localization, and function across different biological contexts .

How should SOX5 antibodies be stored and handled to maintain optimal activity?

To maintain optimal activity of SOX5 antibodies, proper storage and handling are essential. SOX5 antibodies should be stored at -20°C in a buffer containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3. Under these conditions, the antibodies remain stable for one year after shipment. Importantly, aliquoting is unnecessary for storage at -20°C, which simplifies laboratory management. When using antibodies supplied in 20μl sizes, researchers should note that these contain 0.1% BSA. Before use, antibodies should be gently thawed and briefly centrifuged to collect the solution at the bottom of the tube. Repeated freeze-thaw cycles should be avoided as they can lead to protein denaturation and loss of antibody activity. When handling the antibody, researchers should use clean, RNase/DNase-free tubes and pipette tips to prevent contamination .

How are SOX5 antibodies utilized in autoimmunity research, particularly in psoriatic arthritis studies?

SOX5 antibodies have emerged as important tools in autoimmunity research, particularly in studying psoriatic arthritis (PsA) where SOX5 has been identified as a novel autoantigen. In pioneering research, anti-SOX5 antibodies were detected in 8.9% (12/135) of patients in a PsA discovery cohort and 4.3% (14/323) in a validation cohort, compared to only 2.4% (1/41) in healthy controls. These studies employed multiple methodological approaches including immunoprecipitation with radiolabeled cell lysates followed by mass spectrometry for autoantigen discovery, in vitro transcription and translation (IVTT) for validation, and ELISA for high-throughput screening. The detection of anti-SOX5 antibodies has enabled researchers to identify potential mechanistic subgroups within PsA populations, as these antibodies showed significant association with female sex (15.7% in women vs. 2.6% in men, p=0.006 in discovery cohort), suggesting sex-specific disease mechanisms. Furthermore, patients with anti-SOX5 positivity demonstrated different treatment profiles, being more likely to receive biologic disease-modifying antirheumatic drugs (95% vs. 61%, p=0.001) and showing varied responses to different treatment mechanisms, particularly IL-23 inhibitors .

What methodological approaches are used to validate SOX5 antibody specificity in research applications?

Validation of SOX5 antibody specificity requires a multi-faceted approach that combines several complementary techniques. The gold standard methodology involves immunoprecipitation (IP) using 35S-methionine-labeled in vitro transcription and translation (IVTT) proteins, where DNA encoding full-length human SOX5 is used to generate labeled proteins that can be specifically immunoprecipitated by anti-SOX5 antibodies. To rule out false-positive results, researchers should conduct negative controls using healthy control sera and additional specificity controls, such as performing IPs with a mixture of distinct proteins (e.g., SOX5, MDA5, RNPC3, SAE1, and PCNA) to confirm that anti-SOX5 positive sera specifically immunoprecipitate only SOX5. For broader application in high-throughput settings, enzyme-linked immunosorbent assays (ELISAs) can be optimized using recombinant full-length human SOX5 protein expressed in systems distinct from those used for antibody generation (e.g., HEK293T cells). The agreement between IVTTIP and ELISA methods should be quantified using statistical measures such as the kappa statistic, with high agreement values (κ = 0.822, p < 0.001 for SOX5) indicating robust validation. Additionally, antibody specificity should be confirmed through knockdown/knockout experiments in relevant cell lines, with at least three independent validations recommended for high confidence .

How do SOX5 antibodies contribute to understanding the relationship between SOX5 and cancer pathogenesis?

SOX5 antibodies have become instrumental in elucidating the complex relationship between SOX5 and cancer pathogenesis across multiple malignancies. Through immunohistochemical analyses of tumor tissues, researchers have established differential expression patterns of SOX5 in various cancer types including prostate cancer, glioblastoma, hepatocellular carcinoma, osteosarcoma, and nasopharyngeal carcinoma. Western blotting applications using specific SOX5 antibodies have enabled quantitative assessment of SOX5 expression levels in cancer cell lines such as A549, SH-SY5Y, and U-87 MG, providing insights into its regulation in different cellular contexts. Beyond mere expression analysis, functional studies incorporating SOX5 knockdown approaches verified by antibody detection have revealed its role in critical cancer-related processes including proliferation, invasion, metastasis, and stemness. The specificity of SOX5 antibodies has allowed researchers to distinguish between different isoforms (42, 71, and 82-84 kDa) that may have distinct functions in cancer progression. Furthermore, chromatin immunoprecipitation (ChIP) experiments using SOX5 antibodies have identified downstream target genes regulated by SOX5 in cancer cells, establishing regulatory networks that contribute to malignant phenotypes. This multifaceted approach has positioned SOX5 as a potential biomarker and therapeutic target in multiple cancer types .

What optimization strategies should be employed for Western Blotting with SOX5 antibodies?

Optimizing Western Blotting protocols for SOX5 antibodies requires systematic adjustment of several parameters to achieve specific signal detection while minimizing background. First, researchers should determine the optimal antibody dilution within the recommended range (1:2000-1:10000) through titration experiments for each specific cell type or tissue. Sample preparation is critical; complete lysis buffers containing protease inhibitors should be used to prevent degradation of SOX5 protein, which can be particularly important when analyzing the multiple isoforms (42, 71, and 82-84 kDa). For gel electrophoresis, 8-10% polyacrylamide gels are recommended to achieve optimal separation of the higher molecular weight SOX5 isoforms (68-70 kDa). During the transfer step, extended transfer times (90-120 minutes) at lower voltages may improve the efficiency for these larger proteins. Blocking conditions should be optimized; while 5% BSA in PBST is commonly effective, researchers may need to test alternative blocking agents if background issues persist. Positive controls should include lysates from cells known to express SOX5 (such as A549, SH-SY5Y, or U-87 MG cells, or mouse liver tissue). For validation of antibody specificity, knockdown/knockout experiments are essential to confirm that bands disappear or diminish in intensity when SOX5 expression is reduced, as has been documented in multiple published studies using SOX5 antibodies .

How can researchers effectively design ELISA protocols for detecting anti-SOX5 autoantibodies in patient samples?

Designing effective ELISA protocols for detecting anti-SOX5 autoantibodies in patient samples requires careful consideration of multiple technical parameters. Based on validated research methodologies, wells should be coated with precisely 50 ng per well of recombinant full-length human SOX5 protein, preferably expressed in mammalian systems such as HEK293T cells to ensure proper folding and post-translational modifications. Overnight coating at 4°C provides optimal protein adsorption to the plate surface. Following coating, thorough washing with phosphate buffered saline containing 0.05% Tween (PBST) and blocking with 5% bovine serum albumin (BSA) in PBST is essential to minimize non-specific binding. Patient sera should be diluted 1:200 in 1% BSA/PBST and incubated for one hour at room temperature, followed by detection with horseradish peroxidase-labeled anti-human IgG at a 1:10,000 dilution. For result standardization, each assay should include a positive reference serum with optical density in the linear range, allowing calibration across multiple plates and experiments. The cutoff for antibody positivity should be rigorously established as the optical density representing three standard deviations above the mean of healthy controls (typically n ≥ 40). This standardized approach ensures reliable detection of anti-SOX5 autoantibodies with minimal false positives or negatives, as demonstrated in clinical studies examining autoantibody prevalence in conditions such as psoriatic arthritis .

What are the technical considerations for immunoprecipitation assays using SOX5 antibodies?

Immunoprecipitation (IP) assays with SOX5 antibodies require meticulous attention to technical details to ensure sensitivity and specificity. When employing radiolabeled cell lysates for discovery approaches, researchers should select appropriate cell lines expressing SOX5 (such as 624 melanoma cells) and optimize labeling conditions to achieve sufficient incorporation of 35S-methionine. For scaled-up protein amounts in unlabeled IPs intended for mass spectrometry analysis, on-bead digestion techniques provide superior results compared to elution-based approaches. When validating SOX5 as a target antigen, in vitro transcription and translation (IVTT) using DNA encoding full-length human SOX5 generates 35S-methionine-labeled proteins that serve as defined input for IP validation. Critical controls must include IPs performed with healthy control sera to establish background levels, and specificity controls using mixtures of distinct IVTT proteins (e.g., SOX5, MDA5, RNPC3, SAE1, and PCNA) to confirm selective immunoprecipitation of SOX5 by anti-SOX5 positive sera. Gel electrophoresis conditions should be optimized to resolve the specific molecular weight range of SOX5 (68-70 kDa), with extended running times if necessary. The agreement between IP results and other detection methods such as ELISA should be quantified using statistical measures like the kappa statistic, with high agreement values (κ = 0.822, p < 0.001 for SOX5) indicating robust validation across platforms .

How do anti-SOX5 autoantibodies correlate with clinical features and treatment responses in autoimmune diseases?

Anti-SOX5 autoantibodies demonstrate significant correlations with specific clinical features and treatment responses in autoimmune diseases, particularly in psoriatic arthritis (PsA). Comprehensive clinical studies have revealed a strong sex-based association, with anti-SOX5 antibodies more prevalent in female patients across multiple cohorts (discovery cohort: 15.7% women vs. 2.6% men, p=0.006; validation cohort: 6.3% women vs. 1.4% men, p=0.049). This consistent gender disparity suggests underlying sex-specific disease mechanisms that merit further investigation. Longitudinal analyses adjusted for sex have demonstrated that patients with anti-SOX5 positivity are significantly more likely to receive biologic disease-modifying antirheumatic drugs (bDMARDs) compared to antibody-negative patients (95% vs. 61%, p=0.001), indicating potentially more aggressive disease requiring advanced therapeutic intervention. Treatment mechanism analysis revealed that anti-SOX5-positive patients were more likely to be treated with IL-23 inhibitors at baseline (20% vs. 3%, p=0.049) and less likely to be on biologics other than TNF/IL-17/IL-23 inhibitors both at baseline (20% vs. 41%, p=0.039) and longitudinally (13% vs. 41%, p=0.003). These differential treatment patterns suggest that anti-SOX5 antibodies may identify mechanistic subgroups within the broader PsA population that respond differently to specific therapeutic approaches. The table below summarizes these clinical correlations:

These findings highlight the potential utility of anti-SOX5 antibodies as biomarkers for disease stratification and personalized treatment approaches in autoimmune diseases .

How does the prevalence of anti-SOX5 antibodies compare across different autoimmune conditions?

The prevalence of anti-SOX5 antibodies varies significantly across different autoimmune conditions, providing insights into potential disease mechanisms and overlaps. Systematic enzyme-linked immunosorbent assay (ELISA) screening has revealed distinct patterns of anti-SOX5 antibody positivity across multiple patient cohorts. In psoriatic arthritis (PsA), the prevalence was found to be 8.9% (12/135) in the discovery cohort and 4.3% (14/323) in the validation cohort, demonstrating consistency across independent patient populations despite some variation that may relate to differences in disease duration (means of 13.6 vs. 6.5 years, respectively) and treatment exposure. Interestingly, patients with psoriasis without arthritic manifestations showed an even higher prevalence of 12.5% (3/24), suggesting that these antibodies may be associated with the dermatological aspects of the disease spectrum. In comparison, other autoimmune conditions such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) both demonstrated a prevalence of 7.6% (5/66 for each condition), indicating a significant presence across multiple autoimmune diseases. Healthy controls exhibited the lowest prevalence at 2.4% (1/41), establishing a clear differentiation between disease and non-disease states. This cross-disease comparison suggests that anti-SOX5 antibodies may represent a shared autoimmune phenomenon with varying relevance to different conditions, potentially reflecting common pathogenic mechanisms. The prevalence data is summarized in the following table:

These comparative prevalence data provide valuable insights for researchers investigating the role of SOX5 in autoimmunity across different disease contexts .

What is the relationship between SOX5 antibodies and other autoantibodies in autoimmune disease research?

The relationship between anti-SOX5 antibodies and other autoantibodies in autoimmune disease research reveals important insights into disease heterogeneity and pathogenic mechanisms. Detailed analysis of autoantibody profiles has demonstrated that SOX5 antibodies often coexist with antibodies targeting related SOX-D family transcription factors, including SOX6 and SOX13, suggesting recognition of conserved epitopes across this protein family. The high degree of overlap among anti-SOX5, anti-SOX6, and anti-SOX13 specificities in antibody-positive patients indicates potential cross-reactivity or concurrent immune responses against structurally similar proteins. Importantly, research has shown that anti-SOX5 antibodies represent a distinct serological subset from other known autoantibody specificities. For example, in psoriatic arthritis, among patients positive for anti-ADAMTS-L5 antibodies (another recently identified autoantigen), seven out of eight (87.5%) were negative for anti-SOX5 antibodies, indicating largely non-overlapping patient subsets. This pattern suggests that different autoantibody specificities may define discrete pathogenic mechanisms within the broader disease classification. The distinct nature of these autoantibody responses is further supported by the finding that anti-SOX5 antibodies show specific demographic associations (female predominance) and treatment response patterns (increased biologic DMARD usage and differential response to IL-23 inhibitors) that may not apply to patients with other autoantibody specificities. These findings highlight the importance of comprehensive autoantibody profiling in autoimmune diseases to identify mechanistically distinct patient subgroups that may benefit from tailored therapeutic approaches .

What are common challenges in Western Blotting with SOX5 antibodies and how can they be resolved?

Western Blotting with SOX5 antibodies can present several technical challenges that require systematic troubleshooting. A common issue is the detection of multiple bands, which may result from the presence of multiple SOX5 isoforms (42, 71, and 82-84 kDa), protein degradation, or non-specific binding. To address this, researchers should first optimize protein extraction by using complete lysis buffers containing protease inhibitors and maintaining samples at cold temperatures throughout processing. Non-specific binding can be reduced by optimizing blocking conditions (testing 5% BSA versus 5% non-fat dry milk) and antibody dilutions (starting with the recommended 1:2000-1:10000 range and adjusting as needed). If background remains problematic, increasing the number and duration of wash steps with PBST can improve signal-to-noise ratio. For weak or absent signals, researchers should verify SOX5 expression in their experimental system, as expression levels vary across cell types (with confirmed expression in A549, SH-SY5Y, and U-87 MG cells, and mouse liver tissue). Loading sufficient protein (typically 20-40 μg per lane) and optimizing transfer conditions for higher molecular weight proteins (using lower voltage for longer duration) can enhance detection of the 68-70 kDa SOX5 bands. Additionally, using fresh antibody preparations and ensuring proper storage at -20°C in PBS with 0.02% sodium azide and 50% glycerol will maintain antibody activity. For validation of bands, knockdown/knockout experiments are essential to confirm specificity, as documented in multiple publications using SOX5 antibodies .

How can researchers ensure reproducibility in anti-SOX5 autoantibody detection across different laboratories?

Ensuring reproducibility in anti-SOX5 autoantibody detection across different laboratories requires standardization of multiple methodological aspects. First, a consensus on antigen preparation is essential; laboratories should use full-length recombinant human SOX5 protein (preferably from the same commercial source or produced using identical expression systems such as HEK293T cells) to minimize variability in protein folding and post-translational modifications. ELISA protocols should be standardized with precise specifications for coating concentration (50 ng per well), blocking conditions (5% BSA in PBST), serum dilution (1:200), and detection antibody parameters (HRP-labeled anti-human IgG at 1:10,000). To normalize results across different laboratories and experiments, every assay should include identical reference positive control sera with optical density in the linear range for calibration. The cutoff for antibody positivity should be uniformly defined as optical density exceeding three standard deviations above the mean of at least 40 healthy controls. Inter-laboratory validation can be achieved through blind testing of shared sample sets and calculation of concordance statistics such as Cohen's kappa. For confirmatory testing, immunoprecipitation using 35S-methionine-labeled in vitro transcription and translation SOX5 protein represents a gold standard that should yield high agreement (κ > 0.8) with ELISA results. Regular participation in external quality assessment programs specifically designed for autoantibody testing would further enhance standardization. Finally, detailed reporting of all methodological parameters in publications, including lot numbers of critical reagents, will facilitate reproduction of findings across research groups .

What controls and validation steps are essential when implementing new experimental protocols with SOX5 antibodies?

When implementing new experimental protocols with SOX5 antibodies, rigorous controls and validation steps are essential to ensure reliable and interpretable results. First, antibody specificity must be validated through multiple complementary approaches. For Western Blotting applications, positive controls should include lysates from cells known to express SOX5 (such as A549, SH-SY5Y, or U-87 MG cells, or mouse liver tissue), while negative controls should include samples where SOX5 is absent or depleted through siRNA/shRNA knockdown or CRISPR knockout approaches. Isotype controls (non-specific IgG from the same species as the SOX5 antibody) should be included to assess non-specific binding. For immunohistochemistry or immunofluorescence, peptide competition assays can provide additional validation by demonstrating signal reduction when the antibody is pre-incubated with excess SOX5 peptide. When developing new ELISA protocols for autoantibody detection, inter-assay reliability should be established through replicate testing of the same samples across multiple runs, with calculation of coefficients of variation (CV should be <15%). Cross-reactivity assessment is crucial, especially given the sequence homology between SOX5 and other SOX family members; this can be addressed through parallel testing with recombinant SOX6 and SOX13 proteins. For all applications, dose-response relationships should be established to determine the linear detection range. Finally, method comparison studies should be performed, comparing new protocols against established gold standards (such as immunoprecipitation with in vitro transcription and translation proteins) with statistical analysis of agreement using measures such as Cohen's kappa (ideally κ > 0.8). These comprehensive validation steps ensure that new experimental protocols generate reliable and reproducible data across different research settings .

What emerging applications of SOX5 antibodies are being developed in current research?

Emerging applications of SOX5 antibodies are expanding beyond traditional protein detection into innovative research areas. One rapidly developing application is the use of SOX5 antibodies in chromatin immunoprecipitation sequencing (ChIP-seq) to comprehensively map SOX5 binding sites across the genome, revealing its role in transcriptional networks during development and disease. Another frontier is multiplexed imaging technologies, where SOX5 antibodies are being incorporated into cyclic immunofluorescence and mass cytometry panels to analyze SOX5 expression at single-cell resolution within complex tissues, particularly in developmental contexts and tumor microenvironments. In therapeutic development, SOX5 antibodies are enabling target validation studies for novel approaches such as proteolysis targeting chimeras (PROTACs) and antibody-drug conjugates directed against SOX5 in cancer models. The discovery of SOX5 as an autoantigen has also stimulated interest in developing standardized clinical assays for anti-SOX5 autoantibodies as potential biomarkers for disease stratification and treatment selection in autoimmune conditions like psoriatic arthritis. Additionally, researchers are exploring SOX5 antibodies in combination with CRISPR-Cas9 gene editing to investigate the functional consequences of SOX5 mutations identified in human diseases. As single-cell technologies continue to advance, SOX5 antibodies are being adapted for single-cell western blotting and proteomics to examine cell-to-cell variability in SOX5 expression and post-translational modifications. These diverse applications highlight the expanding utility of SOX5 antibodies across multiple cutting-edge research domains .

How might advances in SOX5 antibody technology impact personalized medicine approaches?

Advances in SOX5 antibody technology are poised to significantly impact personalized medicine approaches through several mechanisms. The development of highly sensitive and specific assays for detecting anti-SOX5 autoantibodies is creating new opportunities for patient stratification in autoimmune diseases like psoriatic arthritis (PsA), where anti-SOX5 positivity has been associated with female predominance and distinctive treatment profiles. This could lead to more targeted therapeutic strategies, particularly given the observed differences in treatment with biologic DMARDs (95% vs. 61%, p=0.001) and IL-23 inhibitors (20% vs. 3%, p=0.049) between anti-SOX5 positive and negative patients. As multiplex antibody technologies advance, SOX5 antibody detection could be integrated into comprehensive autoantibody panels that provide "immune signatures" predictive of disease course and treatment response. In oncology, the evolving understanding of SOX5's role in multiple cancer types (prostate cancer, glioblastoma, hepatocellular carcinoma, osteosarcoma, and nasopharyngeal carcinoma) suggests potential applications in tumor classification and prognostication. Enhanced immunohistochemical approaches using SOX5 antibodies could help identify patient subsets likely to benefit from emerging targeted therapies that modulate SOX5-dependent pathways. The integration of SOX5 antibody-based diagnostics with genetic profiling could generate multi-omic predictive models with superior accuracy for personalized therapeutic decision-making. Furthermore, as liquid biopsy technologies advance, detection of circulating SOX5 protein or anti-SOX5 antibodies might offer minimally invasive monitoring capabilities for disease progression and treatment response. These developments collectively demonstrate how advances in SOX5 antibody technology are creating new paradigms for precision medicine across multiple disease contexts .